INFUSYSTEM HOLDINGS, INC Share-based Payment Arrangement, Expense
INFUSYSTEM HOLDINGS, INC (INFU) reported Share-based Payment Arrangement, Expense of $4.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-02-27
- INFUSYSTEM HOLDINGS, INC share-based payment arrangement, expense for fiscal 2025 was $4.36M, a 2.17% decline from fiscal 2024.
- INFUSYSTEM HOLDINGS, INC share-based payment arrangement, expense for fiscal 2024 was $4.46M, a 9.47% increase from fiscal 2023.
- INFUSYSTEM HOLDINGS, INC share-based payment arrangement, expense for fiscal 2023 was $4.07M, a 6.51% increase from fiscal 2022.
- INFUSYSTEM HOLDINGS, INC share-based payment arrangement, expense for fiscal 2022 was $3.83M, a 40.27% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 12 month |
|---|---|
| 2025-12-31 | $4.36M 10-K · filed 2026-02-27 |
| 2024-12-31 | $4.46M 10-K · filed 2026-02-27 |
| 2023-12-31 | $4.07M 10-K · filed 2025-03-11 |
| 2022-12-31 | $3.83M 10-K · filed 2024-04-10 |
| 2021-12-31 | $6.40M 10-K · filed 2024-04-10 |
| 2020-12-31 | $2.61M 10-K · filed 2023-03-16 |
| 2019-12-31 | $997.00K 10-K · filed 2022-03-15 |
| 2012-12-31 | $900.00K 10-K · filed 2013-03-28 |
| 2011-12-31 | $1.20M 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 |